News
Follow us here to see our latest developments in bringing personalized precision care to cancer patients
Sygnomics lands $2 million grant to advance personalized precision oncology solutions.
The Andy Hill Cancer Research Endowment (CARE) Fund awarded a $2 million Life Science Startup Catalyst grant to SYGNOMICS, a personalized precision oncology startup that helps oncologists improve patient
SYGNAL used to characterize treatment-induced evolution of tumor cell states in a single patient
Glioblastoma (GBM) is a heterogeneous tumor made up of cell states that evolve over time. Here, we modeled tumor evolutionary trajectories during standard-of-care treatment using multi-omic single-cell analysis of
Sygnomics and xCures present at 2021 SNO Annual Meeting
Sygnomics in collaboration with xCures presented a poster at 2021 SNO Annual Meeting to demonstrate how systems biology-based predictive cancer models for GBM in combination with real-world data registry
Sygnomics partners with slalom_build to develop a functional prototype of a web-based Precision Oncology platform
Sygnomics partnered with leading global business and technology consulting company, Slalom to provide an end-to-end prototype for Sygnomics Precision Oncology platform. In roughly two months, a team of Builders
A technology to generate a patient-specific disease-relevance network map
The 75 percent failure rate of cancer therapies underscores the need for personalized treatments. No two patients are alike, therefore a sophisticated approach is necessary to accurately predict from
ISB researchers develop first systems scale predictive model for glioblastoma
In a study published (online in advance) in Cell Systems on July 14, 2016, researchers at the Institute for Systems Biology have developed a platform for integrating somatic mutations and gene